IPF News Briefs

blood in test tubes

High KL-6 Level Associated With Disease Progression in IPF

Researchers have discovered that serum Krebs von den Lungen-6 (KL-6) level may be a useful biomarker of disease progression in idiopathic pulmonary fibrosis (IPF), as published in Scientific Reports. IPF is a progressive fibrosing interstitial pneumonia that carries a poor prognosis, with a median survival of only 3 to 5 years. Currently, physiological parameters obtained…

human lungs

New Data Show Antifibrotic Effects of LASN01 for IPF

Lassen Therapeutics announced positive new preclinical data on LASN01, their novel IL-11 receptor-blocking antibody intended to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). The data were presented at the American Thoracic Society Annual Meeting in San Francisco, California on May 17, 2022. “IL-11 is a key biological mediator in many fibrotic diseases including [IPF],”…

group

People With Rare Diseases Report Facing Stigma, Poor Quality of Life

People with rare diseases who live in the United States have a poor health-related quality of life and experience significant stigma, according to a study published in the Orphanet Journal of Rare Diseases. A rare disease in the United States can be defined as any disease in which the prevalence is less than 200,000 cases.…

human lungs

BI 1015550 Slows Lung Function Decline in Phase 2 IPF Study

Boehringer Ingelheim has reported encouraging 12-week phase 2 trial data on their investigational BI 1015550 therapy, a novel phosphodiesterase 4B inhibitor for patients with idiopathic pulmonary fibrosis (IPF). The results, reported via news release, were presented at the American Thoracic Society (ATS) International Conference breaking news session in San Francisco, California on May 16, 2022.…

response curves

LYT-100 Reduces Incidence of Adverse Events in IPF

Additional data from a phase 1 clinical trial of LYT-100 (deupirfenidone) in healthy older adults showed a reduced incidence of adverse events compared to pirfenidone. The data support the initiation of the upcoming phase 2 ELEVATE trial (NCT05321420) of LYT-100 in patients with idiopathic pulmonary fibrosis (IPF). The ELEVATE trial plans to test LYT-100 at…

pulmonary fibrosis

Coadministered Cudetaxestat Shows Potential in IPF Trial

Cudetaxestat is well tolerated and leads to no treatment-related serious adverse events when coadministered with pirfenidone or nintedanib in healthy volunteers, according to the results of a phase 1 clinical trial. There were also no drug-drug interactions with cudetaxestat plus pirfenidone or nintedanib. These results were presented at the American Thoracic Society 2022 International Conference.…

BMI

Malnutrition Associated With Increased Hospitalization and Mortality in IPF

A new study reports that the prevalence of malnutrition in patients with idiopathic pulmonary fibrosis (IPF) is approximately 26%, and it is associated with increased hospitalization and mortality in this population. The study, published in the journal Clinical Nutrition, also reports that gender-age-physiology (GAP) scores, body mass index (BMI), and food intake are independent factors…

lung disease

Inhalational Exposures Common in Patients With Idiopathic Pulmonary Fibrosis

Patients with interstitial lung disease (ILD) subtypes, including idiopathic pulmonary fibrosis (IPF), tend to have inhalational exposures more than half of the time, with a higher risk in male individuals and patients with a family history of ILD, according to a study recently published in Respirology. The study identified the baseline characteristics of almost 4000…

vaccine

Patients With IPF Show Reduced Antibody Responses to COVID-19 Vaccine

Patients with idiopathic pulmonary fibrosis (IPF) do not mount an appreciable antispike antibody response to COVID-19 vaccines, a new study published in ERJ Open Research found. This is the case regardless of antifibrotic treatment in these patients. “This report is of interest given that impaired immune response following vaccination in most diseases has not been…

Next post in IPF News Briefs